Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation after thymoma surgery: does it keep cancer away?

NCT ID NCT04731610

Disease control Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving radiation therapy after surgery can stop thymoma (a rare chest tumor) from returning in patients with stage II or III disease. About 314 adults aged 18-75 who had the tumor completely removed will be randomly assigned to receive radiation or just be watched. The main goal is to see if radiation improves the time without cancer coming back.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 314 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2021

Expected to finish

Dec 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 18 \< Age \< 75 years old 2. ECOG performance status ≤1 3. Preoperative chemotherapy is allowed. Maximum of 4 cycles are authorized. Surgery should be realized ≤ 2 months after the last chemotherapy injection. 4. Histologically diagnosed thymoma at pathological examination of surgical specimen after pathological review; for note, centralized, real-time, systematic pathological review is standard through the RYTHMIC network in France 5. Complete resection at pathological examination of the surgical specimen after surgery conducted through standard, recommended approach ensuring accurate assessment of resection status 6. Stage IIb or III disease according to the Masaoka-Koga staging system; this corresponds to stage pT1a with capsule invasion, until stage pT3 N0 M0 in the 8th TNM staging system TNM UICC/AJCC 7. Availability of thoracic Computed-Tomography (CT) scan with IV contrast (in the absence of contra-indications) or PET scan performed before surgery 8. Availability of a thoracic Computed-Tomography (CT) scan with IV contrast (in the absence of contra-indications) showing absence of residual disease after surgical resection of the tumor 9. Pulmonary function tests after surgery with FEV1 ≥ 1L or ≥ 35% of the theoretical value and DLCO ≥ 40% 10. Signature of informed consent form Exclusion Criteria: \- 1. Age \> 75 years old 2. Histology of thymic carcinoma 3. Delivery of post-operative chemotherapy, concurrent chemotherapy to radiotherapy 4. Presence of microscopic or macroscopic residual tumor after surgery or metastases (R1 or R2 resection) 5. Uncontrolled, clinically significant pleural or pericardial effusion 6. Patients with prior radiation therapy to the thorax. Patients treated with conformal radiotherapy for prior breast or head and neck neoplasms should be discussed with PI 7. Evidence of severe or uncontrolled systemic disease as judged by the investigator 8. Recent (\< 6 months) severe cardiac disease (uncontrolled arrhythmia, congestive heart failure, infarction, pace-maker) or pulmonary disease. Controlled and non clinically symptomatic arrhythmia is allowed. 9\. Current or past history of neoplasm diagnosed within the last 3 years, except: basal cell carcinoma of the skin, in situ carcinoma of the cervix, and bladder in situ. A patient diagnosed for another neoplasm 3 years ago or more, treated and considered as cured may be included in the study if all the other criteria are respected 10. Pregnancy or breast feeding or inadequate contraceptive measures for women of childbearing potential during PORT 11. Patients who, for family, social, geographic or psychological reasons, cannot be adequately followed up and/or are incapable of undergoing regular controls, 12. Patients deprived of freedom or under guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thymoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

invasive malignant thymoma thymic carcinoma thymoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thymoma malignant recurrent

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HM Hôpital Nord

    RECRUITING

    Marseille, 13005, France

  • Antoine LACASSAGNE

    NOT_YET_RECRUITING

    Nice, 06189, France

  • CHRU Tours

    RECRUITING

    Tours, 37044, France

  • CHU Caen

    RECRUITING

    Caen, 14000, France

  • CHU Haut Lévêque

    NOT_YET_RECRUITING

    Pessac, 33604 Cedex, France

  • CHU Lyon

    RECRUITING

    Lyon, 69002, France

  • CHU Rennes Hôpital Sud

    RECRUITING

    Rennes, 35056, France

  • CHU Rouen

    WITHDRAWN

    Rouen, France

  • CHU Strasbourg

    NOT_YET_RECRUITING

    Strasbourg, 67098, France

  • CLCC François BACLESSE

    RECRUITING

    Caen, 14000, France

  • CLCC Georges François Leclerc

    RECRUITING

    Dijon, 21079, France

  • CLCC Henri Becquerel

    NOT_YET_RECRUITING

    Rouen, France

  • Centre Oscar Lambret

    RECRUITING

    Lille, 59000, France

  • Gustave Roussy

    RECRUITING

    Villejuif, 94800, France

  • Hôpital Bichat AP-HP

    RECRUITING

    Paris, 75018, France

  • Hôpital Européen Georges Pompidou

    NOT_YET_RECRUITING

    Paris, 75015, France

  • Institut Claudius Regaud

    RECRUITING

    Toulouse, 31300, France

  • Institut Curie

    RECRUITING

    Paris, 75005, France

  • Institut de Cancérologie de Lorraine Nancy

    RECRUITING

    Vandœuvre-lès-Nancy, 54519, France

  • Institut de Cancérologie de l'Ouest

    RECRUITING

    Saint-Herblain, 44805, France

  • Institut du Cancer de Montpellier

    NOT_YET_RECRUITING

    Montpellier, 34090, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.